Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab

References

• TaoZShiALuCSongTZhangZZhaoJBreast cancer: epidemiology and etiologyCell Biochem Biophys Epub20141228
   Web of Science ®Google Scholar
• DittrichAGautreyHBrowellDTyson-CapperAThe HER2 signaling network in breast cancer-like a spider in its webJ Mammary Gland Biol Neoplasia2014193–425327025544707
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLAStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience198924449057077122470152
   PubMed Web of Science ®Google Scholar
• BaselgaJSwainSMNovel anticancer targets: revisiting ERBB2 and discovering ERBB3Nat Rev Cancer20099746347519536107
   PubMed Web of Science ®Google Scholar
• SubbiahIMGonzalez-AnguloAMAdvances and future directions in the targeting of HER2-positive breast cancer: implications for the futureCurr Treat Options Oncol2014151415424323591
   PubMed Web of Science ®Google Scholar
• GianniLEiermannWSemiglazovVNeoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLancet2010375971237738420113825
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• TolaneySMBarryWTDangCTAdjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancerN Engl J Med2015372213414125564897
   PubMed Web of Science ®Google Scholar
• CardosoFPiccartMJDurbecqVDi LeoAResistance to trastuzumab: a necessary evil or a temporary challenge?Clin Breast Cancer20023424725712425752
   PubMedGoogle Scholar
• KumlerITuxenMKNielsenDLA systematic review of dual targeting in HER2-positive breast cancerCancer Treat Rev201440225927024080156
   PubMed Web of Science ®Google Scholar
• BadacheAHynesNEA new therapeutic antibody masks ErbB2 to its partnersCancer Cell20045429930115093533
   PubMed Web of Science ®Google Scholar
• ErogluZTagawaTSomloGHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerOncologist201419213515024436312
   PubMed Web of Science ®Google Scholar
• RoskoskiRJrThe ErbB/HER family of protein-tyrosine kinases and cancerPharmacol Res201479347424269963
   PubMed Web of Science ®Google Scholar
• RossJSFletcherJAThe HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapyOncologist19983423725210388110
   PubMedGoogle Scholar
• ZuoTWangLMorrisonCFOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogeneCell200712971275128617570480
   PubMed Web of Science ®Google Scholar
• MyersEHillADKellyGMcDermottEWO’HigginsNJYoungLSA positive role for PEA3 in HER2-mediated breast tumour progressionBr J Cancer200695101404140917060941
   PubMed Web of Science ®Google Scholar
• PoweDGAkhtarGHabashyHOInvestigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplificationBreast Cancer Res2009116R9020025767
   PubMed Web of Science ®Google Scholar
• ZhangTZhangHWangYMcGownLBCapture and identification of proteins that bind to a GGA-rich sequence from the ERBB2 gene promoter regionAnal Bioanal Chem20124046–71867187622899247
   PubMed Web of Science ®Google Scholar
• FryWHKotelawalaLSweeneyCCarrawayKL3rdMechanisms of ErbB receptor negative regulation and relevance in cancerExp Cell Res2009315469770618706412
   PubMed Web of Science ®Google Scholar
• SweeneyCCarrawayKL3rdNegative regulation of ErbB family receptor tyrosine kinasesBr J Cancer200490228929314735165
   PubMed Web of Science ®Google Scholar
• SweeneyCMillerJKShattuckDLCarrawayKL3rdErbB receptor negative regulatory mechanisms: implications in cancerJ Mammary Gland Biol Neoplasia2006111899916865534
   PubMed Web of Science ®Google Scholar
• YenLCaoZWuXLoss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growthCancer Res20066623112791128617145873
   PubMed Web of Science ®Google Scholar
• OlayioyeMAUpdate on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family membersBreast Cancer Res20013638538911737890
   PubMed Web of Science ®Google Scholar
• ZhangXGureaskoJShenKColePAKuriyanJAn allosteric mechanism for activation of the kinase domain of epidermal growth factor receptorCell200612561137114916777603
   PubMed Web of Science ®Google Scholar
• BadacheAGoncalvesAThe ErbB2 signaling network as a target for breast cancer therapyJ Mammary Gland Biol Neoplasia2006111132516947083
   PubMed Web of Science ®Google Scholar
• SchulzeWXDengLMannMPhosphotyrosine interactome of the ErbB-receptor kinase familyMol Syst Biol200512005.000816729043
   PubMed Web of Science ®Google Scholar
• DownwardJTargeting RAS signalling pathways in cancer therapyNat Rev Cancer200331112212509763
   PubMed Web of Science ®Google Scholar
• VigilDCherfilsJRossmanKLDerCJRas superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?Nat Rev Cancer2010101284285721102635
   PubMed Web of Science ®Google Scholar
• SamatarAAPoulikakosPITargeting RAS-ERK signalling in cancer: promises and challengesNat Rev Drug Discov2014131292894225435214
   PubMed Web of Science ®Google Scholar
• CoxADFesikSWKimmelmanACLuoJDerCJDrugging the undruggable RAS: mission possible?Nat Rev Drug Discov2014131182885125323927
   PubMed Web of Science ®Google Scholar
• ThorpeLMYuzugulluHZhaoJJPI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targetingNat Rev Cancer201515172425533673
   PubMed Web of Science ®Google Scholar
• FrumanDARommelCPI3K and cancer: lessons, challenges and opportunitiesNat Rev Drug Discov201413214015624481312
   PubMed Web of Science ®Google Scholar
• LiuPChengHRobertsTMZhaoJJTargeting the phosphoinositide 3-kinase pathway in cancerNat Rev Drug Discov20098862764419644473
   PubMed Web of Science ®Google Scholar
• HollanderMCBlumenthalGMDennisPAPTEN loss in the continuum of common cancers, rare syndromes and mouse modelsNat Rev Cancer201111428930121430697
   PubMed Web of Science ®Google Scholar
• SongMSSalmenaLPandolfiPPThe functions and regulation of the PTEN tumour suppressorNat Rev Mol Cell Biol201213528329622473468
   PubMed Web of Science ®Google Scholar
• AgoulnikIUHodgsonMCBowdenWAIttmannMMINPP4B: the new kid on the PI3K blockOncotarget20112432132821487159
   PubMedGoogle Scholar
• Metzger-FilhoOWinerEPKropIPertuzumab: optimizing HER2 blockadeClin Cancer Res201319205552555623942091
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
   PubMed Web of Science ®Google Scholar
• ParkerJSMullinsMCheangMCSupervised risk predictor of breast cancer based on intrinsic subtypesJ Clin Oncol20092781160116719204204
   PubMed Web of Science ®Google Scholar
• PratABianchiniGThomasMResearch-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH studyClin Cancer Res201420251152124443618
   PubMed Web of Science ®Google Scholar
• SchneeweissAChiaSHickishTPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Ann Oncol20132492278228423704196
   PubMed Web of Science ®Google Scholar
• AttardCLPepperANBrownSTCost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in CanadaJ Med Econ201518317318825347449
   PubMed Web of Science ®Google Scholar
• BardiaABaselgaJNeoadjuvant therapy as a platform for drug development and approval in breast cancerClin Cancer Res201319236360637024298066
   PubMed Web of Science ®Google Scholar
• SalgadoRDenkertCCampbellCTumor-Infiltrating lymphocytes and sssociations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO TrialJAMA Oncol20151444845426181252
   PubMed Web of Science ®Google Scholar
• SchneeweissAChiaSHeggREvaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHA-ENA studyBreast Cancer Res2014164R7325005255
   PubMed Web of Science ®Google Scholar
• MajewskiIJNuciforoPMittempergherLPIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancerJ Clin Oncol201533121334133925559818
   PubMed Web of Science ®Google Scholar
• Vazquez-MartinAColomerRBrunetJMenendezJAPharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting ‘HER2 super-expression’ occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cellsInt J Oncol200731476977617786307
   PubMed Web of Science ®Google Scholar
• KoninkiKBarokMTannerMMultiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cellsCancer Lett2010294221121920193978
   PubMed Web of Science ®Google Scholar
• ArribasJBaselgaJPedersenKParra-PalauJLp95HER2 and breast cancerCancer Res20117151515151921343397
   PubMed Web of Science ®Google Scholar
• CastiglioniFTagliabueECampiglioMPupaSMBalsariAMenardSRole of exon-16-deleted HER2 in breast carcinomasEndocr Relat Cancer200613122123216601290
   PubMed Web of Science ®Google Scholar
• MitraDBrumlikMJOkamgbaSUAn oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistanceMol Cancer Ther2009882152216219671734
   PubMed Web of Science ®Google Scholar
• BoseRKavuriSMSearlemanACActivating HER2 mutations in HER2 gene amplification negative breast cancerCancer Discov20133222423723220880
   PubMed Web of Science ®Google Scholar
• RimawiMFSchiffROsborneCKTargeting HER2 for the treatment of breast cancerAnnu Rev Med20156611112825587647
   PubMed Web of Science ®Google Scholar
• ArteagaCLSliwkowskiMXOsborneCKPerezEAPuglisiFGianniLTreatment of HER2-positive breast cancer: current status and future perspectivesNat Rev Clin Oncol201291163222124364
   PubMed Web of Science ®Google Scholar
• FunesMMillerJKLaiCCarrawayKL3rdSweeneyCThe mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3J Biol Chem200628128193101931916690615
   PubMed Web of Science ®Google Scholar
• Price-SchiaviSAJepsonSLiPRat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistanceInt J Cancer200299678379112115478
   PubMed Web of Science ®Google Scholar
• RainaDUchidaYKharbandaATargeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cellsOncogene201433263422343123912457
   PubMed Web of Science ®Google Scholar
• FesslerSPWotkowiczMTMahantaSKBamdadCMUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cellsBreast Cancer Res Treat2009118111312419415485
   PubMed Web of Science ®Google Scholar
• WangSEXiangBZentRQuarantaVPozziAArteagaCLTransforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeletonCancer Res200969247548219147560
   PubMed Web of Science ®Google Scholar
• YamaguchiHChangSSHsuJLHungMCSignaling cross-talk in the resistance to HER family receptor targeted therapyOncogene20143391073108123542173
   PubMed Web of Science ®Google Scholar
• BakerATZlobinAOsipoCNotch-EGFR/HER2 bidirectional cross-talk in breast cancerFront Oncol2014436025566499
   PubMedGoogle Scholar
• HaluskaPCarboniJMTenEyckCHER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924Mol Cancer Ther2008792589259818765823
   PubMed Web of Science ®Google Scholar
• NahtaRYuDHungMCHortobagyiGNEstevaFJMechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancerNat Clin Pract Oncol20063526928016683005
   PubMedGoogle Scholar
• NahtaRYuanLXZhangBKobayashiREstevaFJInsulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cellsCancer Res20056523111181112816322262
   PubMed Web of Science ®Google Scholar
• TaylorMAParvaniJGSchiemannWPThe pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cellsJ Mammary Gland Biol Neoplasia201015216919020467795
   PubMed Web of Science ®Google Scholar
• WuYGintherCKimJExpression of Wnt3 activates Wnt/beta-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cellsMol Cancer Res201210121597160623071104
   PubMed Web of Science ®Google Scholar
• ElsterNCollinsDMToomeySCrownJEustaceAJHennessyBTHER2-family signalling mechanisms, clinical implications and targeting in breast cancerBreast Cancer Res Treat2015149151525542271
   PubMed Web of Science ®Google Scholar
• Lee-HoeflichSTPhamTQDowbenkoDPPM1H is a p27 phosphatase implicated in trastuzumab resistanceCancer Discov20111432633722586611
   PubMed Web of Science ®Google Scholar
• MoodySESchinzelACSinghSPRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signalingOncogene201534162061207124909179
   PubMed Web of Science ®Google Scholar
• DingKBanerjeeATanSArtemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cellsJ Biol Chem201428923160571607124737320
   PubMed Web of Science ®Google Scholar